Oxford Endovascular

Executive Summary

Oxford Endovascular is a UK-based medical device company spun out from Oxford University, developing a next-generation flow-diverter for treating intracranial aneurysms. Its core innovation leverages 'origami engineering' to create a device that conforms better to blood vessel anatomy, potentially improving safety and efficacy compared to existing flow-diverters. The company addresses a significant unmet need in neurovascular intervention, where aneurysm rupture can lead to fatal brain hemorrhage. By enhancing conformability and reducing procedural complications, Oxford Endovascular aims to offer a superior option for patients and interventional neuroradiologists. The company has progressed through preclinical development and is likely preparing for first-in-human clinical trials. The neurovascular device market is competitive, dominated by established players like Medtronic and Stryker, but Oxford's unique origami approach may provide differentiation. The company's early-stage status and lack of disclosed funding suggest it may be seeking investment or partnership to advance clinical programs. Key upcoming milestones include initiating clinical studies and pursuing regulatory approvals in Europe and the US.

Upcoming Catalysts (preview)

• Q1 2027First-in-Human Clinical Trial Initiation or Completion35% success
• Q2 2027CE Mark Approval30% success
• TBDStrategic Partnership or Series A/B Funding40% success